Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease

Animal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated al...

Full description

Bibliographic Details
Main Authors: Megan F. Duffy, Timothy J. Collier, Joseph R. Patterson, Christopher J. Kemp, D. Luke Fischer, Anna C. Stoll, Caryl E. Sortwell
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-09-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnins.2018.00621/full
id doaj-8a2f96a907344e10961e70c441a8467a
record_format Article
spelling doaj-8a2f96a907344e10961e70c441a8467a2020-11-25T00:21:45ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2018-09-011210.3389/fnins.2018.00621402212Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s DiseaseMegan F. Duffy0Timothy J. Collier1Timothy J. Collier2Joseph R. Patterson3Christopher J. Kemp4D. Luke Fischer5Anna C. Stoll6Caryl E. Sortwell7Caryl E. Sortwell8Department of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesMercy Health Hauenstein Neuroscience Medical Center, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesDepartment of Translational Science and Molecular Medicine, Michigan State University, Grand Rapids, MI, United StatesMercy Health Hauenstein Neuroscience Medical Center, Grand Rapids, MI, United StatesAnimal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated alpha-synuclein via germline manipulation or viral vector-mediated overexpression are used to investigate PD pathophysiology and vet novel therapeutics. While these models represented a step forward compared to their neurotoxicant model predecessors, they rely on overexpression of supraphysiological levels of α-syn to trigger toxicity. However, whereas SNCA-linked familial PD is associated with elevated α-syn, elevated α-syn is not associated with idiopathic PD. Therefore, the defining feature of the α-syn overexpression models may fail to appropriately model idiopathic PD. In the last several years a new model has been developed in which α-syn preformed fibrils are injected intrastriatally and trigger normal endogenous levels of α-syn to misfold and accumulate into Lewy body-like inclusions. Following a defined period of inclusion accumulation, distinct phases of neuroinflammation and progressive degeneration can be detected in the nigrostriatal system. In this perspective, we highlight the fact that levels of α-syn achieved in overexpression models generally exceed those observed in idiopathic and even SNCA multiplication-linked PD. This raises the possibility that supraphysiological α-syn expression may drive pathophysiological mechanisms not relevant to idiopathic PD. We argue in this perspective that synucleinopathy triggered to form within the context of normal α-syn expression represents a more faithful animal model of idiopathic PD when examining the role of neuroinflammation or the relationship between a-syn aggregation and toxicity.https://www.frontiersin.org/article/10.3389/fnins.2018.00621/fullParkinson’s diseasealpha-synucleinpreformed fibrilssynucleinopathyanimal models
collection DOAJ
language English
format Article
sources DOAJ
author Megan F. Duffy
Timothy J. Collier
Timothy J. Collier
Joseph R. Patterson
Christopher J. Kemp
D. Luke Fischer
Anna C. Stoll
Caryl E. Sortwell
Caryl E. Sortwell
spellingShingle Megan F. Duffy
Timothy J. Collier
Timothy J. Collier
Joseph R. Patterson
Christopher J. Kemp
D. Luke Fischer
Anna C. Stoll
Caryl E. Sortwell
Caryl E. Sortwell
Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
Frontiers in Neuroscience
Parkinson’s disease
alpha-synuclein
preformed fibrils
synucleinopathy
animal models
author_facet Megan F. Duffy
Timothy J. Collier
Timothy J. Collier
Joseph R. Patterson
Christopher J. Kemp
D. Luke Fischer
Anna C. Stoll
Caryl E. Sortwell
Caryl E. Sortwell
author_sort Megan F. Duffy
title Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_short Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_full Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_fullStr Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_full_unstemmed Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
title_sort quality over quantity: advantages of using alpha-synuclein preformed fibril triggered synucleinopathy to model idiopathic parkinson’s disease
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2018-09-01
description Animal models have significantly advanced our understanding of Parkinson’s disease (PD). Alpha-synuclein (α-syn) has taken center stage due to its genetic connection to familial PD and localization to Lewy bodies, one pathological hallmark of PD. Animal models developed on the premise of elevated alpha-synuclein via germline manipulation or viral vector-mediated overexpression are used to investigate PD pathophysiology and vet novel therapeutics. While these models represented a step forward compared to their neurotoxicant model predecessors, they rely on overexpression of supraphysiological levels of α-syn to trigger toxicity. However, whereas SNCA-linked familial PD is associated with elevated α-syn, elevated α-syn is not associated with idiopathic PD. Therefore, the defining feature of the α-syn overexpression models may fail to appropriately model idiopathic PD. In the last several years a new model has been developed in which α-syn preformed fibrils are injected intrastriatally and trigger normal endogenous levels of α-syn to misfold and accumulate into Lewy body-like inclusions. Following a defined period of inclusion accumulation, distinct phases of neuroinflammation and progressive degeneration can be detected in the nigrostriatal system. In this perspective, we highlight the fact that levels of α-syn achieved in overexpression models generally exceed those observed in idiopathic and even SNCA multiplication-linked PD. This raises the possibility that supraphysiological α-syn expression may drive pathophysiological mechanisms not relevant to idiopathic PD. We argue in this perspective that synucleinopathy triggered to form within the context of normal α-syn expression represents a more faithful animal model of idiopathic PD when examining the role of neuroinflammation or the relationship between a-syn aggregation and toxicity.
topic Parkinson’s disease
alpha-synuclein
preformed fibrils
synucleinopathy
animal models
url https://www.frontiersin.org/article/10.3389/fnins.2018.00621/full
work_keys_str_mv AT meganfduffy qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT timothyjcollier qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT timothyjcollier qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT josephrpatterson qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT christopherjkemp qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT dlukefischer qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT annacstoll qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT carylesortwell qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
AT carylesortwell qualityoverquantityadvantagesofusingalphasynucleinpreformedfibriltriggeredsynucleinopathytomodelidiopathicparkinsonsdisease
_version_ 1725361063538458624